Find insight on Hims & Hers Health, EssilorLuxottica, Bayer and more in the latest Market Talks covering Health Care.

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Senate To Begin Marathon Vote Series On Trump's "Big, Beautiful Bill" As GOP Eyes July 4 Deadline The Senate is set to kick off what's expected to be a marathon session Monday, after the chamber ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.